Earnings
Stada is reviewing potential M&A for its Consumer Healthcare business, which last year grew its sales despite a weak cough & cold season.
Distribution deals helped Galenica grow its OTC sales in 2025 despite lower demand for cold and flu products.
Higher sales of dietary supplements in key markets like the US and China helped Reckitt's Self-Care business to grow in 2025 despite a weak cold & flu season.
Bayer Consumer Health will lean on its "road to billions" strategy to achieve growth in 2026 against a volatile market backdrop.
“Infant formula has consumed cash” and “at the end of the day, we need to be committed to improve our cash flow,” says CFO Eduardo Bezerra as Perrigo continues reviewing it options for the business.
Haleon's growth rate suffered in 2025 as consumer confidence sank in key markets like North America and Europe.
Moberg's success in Scandinavia gives the company the confidence that its upcoming expansion across Europe will be a success.
Sana Alajmovic is seeing strong interest from potential partners to launch virus-blocking mouth spray ColdZyme in new markets around the world.
Increased sales of dietary supplements softened France’s 2025 volume decline, which was driven by a mild respiratory season. French self-care industry association NèreS calls for expanded pharmacist authority and broader non‑prescription access to strengthen the country’s first line of care.
While Italy’s non-prescription medicines market has stabilized following the volatility of the coronavirus pandemic, unlocking sustainable volume growth will require further Rx-to-OTC switches, argues the country's consumer health industry association, Assosalute.
UK development firm's future looks more secure as it is granted notice of allowance of US continuation patent for Eroxon.
Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.
C&D starts 2026 with expectations to boost sales of latest acquisition, Touchland scented hand sanitizer, after halting sales of Flawless hair removal/nail care and Waterpik showerhead products and selling Spinbrush power toothbrush brand as well vitafusion and L’il Critter gummy supplement lines.
Key divestments have given the UK's Venture Life the financial firepower to pursue M&A this year, with a number of options under review across categories such as women's health and energy management.
“We remain fully committed to the integrated growth strategy that has enabled us to deliver significant growth and value creation, over the better part of the past decade,” says CEO Shailesh Jejurikar as firm reports net sales up 1% in latest quarter.
Bayer expects Consumer Health sales for the full year to advance by 1% at best due to increasingly challenging conditions in its two largest markets.
Dental guards already accounted for “well over half of the brand’s revenue” and DenTek claimed more than 50% of US category share when PCH launched "Fantasy Guards" campaign targeting fantasy football league enthusiasts.
Perrigo pauses $240m spending planned for formula business as it considers options to be in better position to boost growth on OTC drugs. “Problems make formula manufacturing’s “long-term fit alongside our faster-growing, higher-cash-yielding consumer health OTC portfolio less strategic,” says presi
With Q3 results, C&D increases full-year forecast for reported sales growth to around 1.5% after guiding 1% in July. Considering options for cutting its losses linked to its slow-selling product line, C&D also adding revenue growth from adding Touchland scented hand sanitizer brand.
Enzymatica says it is taking "longer than we expected" to sign up partners to launch its ColdZyme innovation across North America and Asia.